Le Lézard9 小时
Pulmatrix and Cullgen Announce Proposed Merger
Cullgen is also evaluating CG009301, a GSPT1 degrader for the treatment of blood cancers including relapsed/refractory acute myeloid leukemia (AML), higher-risk ... The Company's proprietary product ...
Finanznachrichten7 小时
Pulmatrix Inc.: Pulmatrix and Cullgen Announce Proposed Merger
Cullgen is also evaluating CG009301, a GSPT1 degrader for the treatment of blood cancers including relapsed/refractory acute myeloid leukemia (AML), higher-risk ... The Company's proprietary product ...